Evaluation of Immunochemotherapy Effects of Apigenin in Female Balb/c Mice with Breast Cancer

Document Type : Original Article (s)

Authors

1 Professor, Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

2 PhD Student, Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

Abstract

Background: Among the various methods of cancer treatment, the method is more considered which has the most toxicity on the cancerous cells and the minimal side effects on patients’ healthy cells. Flavonoids are polyphenolic compounds which due to their biochemical and therapeutic effects have attracted scientists’ attention. This study aimed to investigate the immunomodulatory effects of apigenin as a flavonoid in anti-tumor immunity and tumor-growth inhibition.Methods: This study was carried out on Balb/c tumor-bearing mice, aged from six to eight weeks. First, the optimized dose of apigenin was determined through delayed-typed hypersensitivity (DTH) test. Then, breast cancer tumor were induced through tissue transplant method and after 12 days of treatment, their spleen lymphocyte proliferation and spleen lymphocyte cytokine production were assessed via measuring the amounts of interleukin-4 (IL-4) and gamma interferon (IFN-γ).Findings: Apigenin caused an increased delayed-typed hypersensitivity (P < 0.05), decreased tumor volume (P < 0.05), increased the IFN-γ level (P < 0.05) and decreased the IL-4 level (P < 0.05). As well as the lymphocyte proliferation in apigenin-treated mice increased significantly in comparison to the control group (P < 0.05).Conclusion: Apigenin can cause an increased delayed-typed hypersensitivity in Balb/c female mice and decreased tumor-growth in tumor-bearing mice and can alter the cytokine ratio to IFN-γ. Increase of IFN-γ and decrease of IL-4 in apigenin-treated mice show that apigenin can switch the mouse immune system towards Th1 and cell-mediated immune responses. Considering this issue can be expected that apigenin is a proper drug for cancer treatment.

Keywords

References

  1. Kamatou GPP, van Zyl RL, Davids H, van Heerden FR, Lourens ACU, Viljoen AM. Antimalarial and anticancer activities of selected South African Salvia species and isolated compounds from S. radula. South African Journal of Botany 2008; 74(2): 238-43.
  2. Tezuka Y, Stampoulis P, Banskota AH, Awale S, Tran KQ, Saiki I, et al. Constituents of the Vietnamese medicinal plant Orthosiphon stamineus. Chem Pharm Bull (Tokyo) 2000; 48(11): 1711-9.
  3. Gohari AR, Saeidnia S, Malmir M, Hadjiakhoondi A, Ajani Y. Flavones and rosmarinic acid from Salvia limbata. Nat Prod Res 2010; 24(20): 1902-6.
  4. Peterson J, Dwyer J. Flavonoids: Dietary occurrence and biochemical activity. Nutrition Research 1998; 18(12): 1995-2018.
  5. Rajnarayana K, Reddy MS, Chaluvadi MR, Krishna DR. Bioflavonoids classification, pharmacological, biochemical effects and therapeutic potential. Indian J Pharmacol 2001; 33(1): 2-16.
  6. Markham KM. Flavones, Flavonols and their Glycosidcs. In: Harborne JB, editor. Methods in plant biochemistry. New York, NY: Academic Press; 2012. p. 197.
  7. Andersen OM, Markham KR. Flavonoids: Chemistry, biochemistry and applications. Boca Raton, FL: CRC Press; 2010.
  8. Agrawal AD. Pharmacological activities of flavonoids: A review. Int J Pharm Sci Nanotech 2011; 4(2): 1394-8.
  9. Krueger RJ. Flavonoids: Chemistry, biochemistry and applications. Economic Botany 2007; 61(1): 101.
  10. Cook NC, Samman S. Flavonoids Chemistry, metabolism, cardioprotective effects, and dietary sources. J Nutr Biochem 1996; 7(2): 66-76.
  11. Pauff JM, Hille R. Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod 2009; 72(4): 725-31.
  12. Grotewold E. The science of flavonoids. New York, NY: Springer; 2006.
  13. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. J Clin Invest 2007; 117(1): 60-9.
  14. Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006; 107(1): 301-4.
  15. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010; 24(1): 22-32.
  16. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118(6): 1991-2001.
  17. Firestone GL, Sundar SN. Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev Mol Med 2009; 11: e32.
  18. Zitvogel L, Kroemer G. Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. J Clin Invest 2009; 119(8): 2127-30..
Journal of Isfahan Medical School
Volume 33, Issue 358 - Serial Number 358
September and October 2016
Pages 1891-1897

Files

History

  • Receive Date: 18 February 2015
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics